Product overview with focus on rare and special diseases.
AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases.
is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder.
Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
is used to treat pulmonary arterial hypertension in adults.
Anagrelide AOP is indicated in Essential Thrombocythemia for the reduction of elevated platelet counts and associated clinical symptoms in at high risk patients
Argipressin AOP is used to treat diabetes insipidus and bleeding from enlarged veins in the oesophagus.
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
Canemes® is indicated for the treatment of nauseas and vomiting in adults who do not adequately respond to other anti-emetic treatment options.
Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.